Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a parallel, double-blind and randomized trial of 6-weeks' duration, flurbiprofen (150 mg to 200 mg daily) was compared with indomethacin (75 mg to 100 mg daily) in the management of 26 patients with active ankylosing spondylitis. None of the patients in either group withdrew from the study because of lack of efficacy of the drugs. Both drugs were equally effective in the relief of pain and tenderness of the affected joints. Overall subjective improvement, assessed by the patient and the investigator at the end of the trial, was present in 90% of the patients in the flurbiprofen group and in 75% of those in the indomethacin group. The mean values of all the spinal motion tests improved in the flurbiprofen group but not in the indomethacin group. Statistically significant improvement in the Schober test was achieved in the flurbiprofen group and in chest expansion in the indomethacin group. Characteristic untoward effects related to the central nervous system and gastro-intestinal tract were present in a few patients in both groups.
 ...
PMID:Treatment of ankylosing spondylitis with flurbiprofen and indomethacin. 7 69

A double-blind trial was carried out in 15 patients with ankylosing spondylitis and 15 with coxarthrosis to assess the effectiveness of 300 mg flurbiprofen daily, administered in divided doses either twice or 3-times a day. Patients were allocated at random to receive treatment for 7 days either with a morning and evening dose of 150 mg flurbiprofen plus a mid-day dose of placebo, or with 3 doses of 100 mg flurbiprofen. They were then crossed over to the alternative regimen for a further 7 days. The results, evaluated by a 5-point rating scale of pain severity and of functional activity and by overall patient and doctor assessments, showed that flurbiprofen was effective in 66% of the 26 patients completing the trial. Tolerance was also assessed as being satisfactory in 83% of all patients. Comparison of the two treatment periods showed that 2 daily doses of flurbiprofen produced as good results as the 3-times daily regimen.
 ...
PMID:Comparative study of the effectiveness of flurbiprofen given twice or 3-times daily. 7 71

Subcutaneous rhizolysis is defined as cutting the nerves to the posterior intervertebral joints. Although a blind procedure, it has proved safe in several centres and provides relief of pain in about two thirds of those who suffer from intractable, persistent backache. Some conditions such as ankylosing spondylitis and previous spinal fusion are clinically unsuitable, but this technique, which is described, is recommended for consideration before all major surgical procedures for back pain are undertaken.
 ...
PMID:A study of subcutaneous rhizolysis in the treatment of chronic backache. 12 40

Highly significant improvement of symptoms was found during treatment with clofezone (Perclusone) over a period of 4 weeks in 56 in-patients with various rheumatic diseases, particularly rheumatoid arthritis (RA), ankylosing spondylitis (AS), and lumbar and cervical syndromes. During the first week clofezone was given at a daily dosage of 1200 mg and thereafter 600 mg. At the same time 21 of the patients with RA and 13 with AS received ACTH injections (0.25 mg twice a week). Already after the first week of treatment a highly significant decrease of disease activity was noticed, as judged by the amount of pain, inhibition of movements, joint swelling and erythrocyte sedimentation rate. The latter decreased on an average by 50% during the treatment period indicating a reduction of the inflammatory process. 51 of the 56 patients showed a satisfactory to very good tolerance of the treatment. Clofezone was discontinued in 5 patients during the first week, because gastro-intestinal intolerance occurred with the 1200 mg dosage. One of these 5 patients tolerated the smaller dosage later. As 3 of the 5 patients belonged to the RA and AS groups, the ACTH administration also has to be considered with regards to the intolerance. Because of possible side effects the higher dosage of clofezone should be given as short term treatment of highly active disease processes only. Clofezone reduced the serum uric acid level in 38 of 45 patients. Pathologically increased levels were reduced to normal in 15 of 17 patients.
 ...
PMID:[Experiences in the management of rheumatoid diseases using different clofezone doses]. 13 65

The majority of patients with a recent onset of back pain that developed rapidly over a few hours have nonspecific spinal disease. The disorder is likely to be self-limited. In contrast, patients presenting with an insidious onset of pain that has lasted for several weeks may have ankylosing spondylitis. Since management differs for the two types of disease, the correct diagnosis is mandatory. The diagnosis of ankylosing spondylitis is confirmed radiologically.
 ...
PMID:Back pain: mechanical or inflammatory? 15 67

For the physiotherapy of rheumatic diseases principles of order are recommended. The aims of physiotherapy (allevition of pain, improvement of mobility, inhibition of inflammation), dosages of physiotherapy (intensity of treatment, time of treatment, region of treatment), quantification of pain and reaction to treatment are in the foreground in these cases. With regard to an appropriate choice of methods these principles of order are explained at the instance of the rheumatoid arthritis and the ankylosing spondylitis. Concerning the rheumatism of the soft tissues a classification of the therapy according to localisation and course of the disease (acute, recurrent, chronic) is explained.
 ...
PMID:[Physical therapy in rheumatic diseases]. 30 82

Though it may be true that, in the absence of a dependable cause, there is no single cure for inflammatory diseases of the locomotor system, nevertheless there is no reason for therapeutic nihilism. Much can be done to induce a remission in the disease while at the same time suppressing inflammation, relieving pain, preventing or correcting deformities, easing stiffness and increasing muscular control of the joints. However, no drug regime can be expected to achieve this, and reliance on drugs alone invariably leads to disappointing results, both for the doctor and patient. Hence every patient also should have a properly organized and supervised regime of physical methods of treatment. The relative value of rest or exercise remains controversial, and different considerations play a role in some of the disease processes. Thus in patients with active rheumatoid synovitis there seems no doubt that at first, extra rest to the inflamed joints is essential, but as the disease process is brought under control, the patient can be mobilized and made more active. In patients with ankylosing spondylitis, the emphasis should be placed on activity and exercise.
 ...
PMID:Rheumatic disease: exercise or immobilization? 30 27

Flurbiprofen (150-200 mg daily) and phenylbutazone (300-400 mg daily) were compared in the management of 27 patients with active ankylosing spondylitis. This was a parallel, double-blind, and randomized trial of 6 weeks duration. Both drugs were equally effective in the relief of pain and tenderness of the affected joints. Overall subjective improvement, assessed by the patient and the investigator at the end of the trial, favored phenylbutazone, but it did not reach a statistically significant level. The mean values of the endpoint parameters of spinal motion showed statistically significant improvement in both groups, except in the Schober test in the flurbiprofen group and chest expansion in the phenylbutazone group. Untoward effects characteristic of these drugs were found in a few patients.
 ...
PMID:Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. 32 73

The effects of flurbiprofen (150-200 mg daily) and indomethacin (75-100 mg daily) were compared in the management of 26 patients with active ankylosing spondylitis in a parallel, double-blind, and randomized trial of six weeks' duration. No patient in either group withdrew from the study because of lack of efficacy of the drugs. Both drugs were equally effectivein relieving the pain and tenderness of the affected joints. Overall subjective improvement, assessed by the patient and the investigator at the end of the trial, was present in 90% of the patients in the flurbiprofen group and in 75% of the indomethacin group. The mean values of all the spinal motion tests improved in the flurbiprofen group but not in the indomethacin group. Statistically significant improvement of the Schober test was achieved in the flurbiprofen group and of the chest expansion measurement in the indomethacin group. Untoward effects related to the central nervous system and gastrointestinal tract were present in a few patients in both groups.
 ...
PMID:Management of ankylosing spondylitis with flurbiprofen or indomethacin. 32 22

Feprazone, a non-steroidal anti-inflammatory drug, was compared with indomethacin in a double-blind cross-over trial in 24 patients with ankylosing spondylitis, over eight weeks. Both regimes caused significant reduction in pain. There were fewer side-effects and more patient preferences with feprazone but these differences did not reach statistical significance.
 ...
PMID:A trial of feprazone in ankylosing spondylitis. 33 40


1 2 3 4 5 6 7 8 9 10 Next >>